{
    "clinical_study": {
        "@rank": "47037", 
        "arm_group": [
            {
                "arm_group_label": "Riluzole", 
                "arm_group_type": "Experimental", 
                "description": "The maximum dose of riluzole to be used in this study is 200 mg per day divided BID"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo will be administered in the same manner as the riluzole group, in order to maintain subject assignment throughout the study."
            }
        ], 
        "brief_summary": {
            "textblock": "Determine if riluzole shows evidence of efficacy, safety, and tolerability targeting\n      drug-refractory irritability (DRI) in persons with autism spectrum disorders (ASD)."
        }, 
        "brief_title": "Pilot Study of Riluzole for Drug-Refractory Irritability in Autism Spectrum Disorders", 
        "completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Autism Spectrum Disorders", 
        "condition_browse": {
            "mesh_term": [
                "Autistic Disorder", 
                "Child Development Disorders, Pervasive"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age \u2265 12 and < 26 years.\n\n          -  Weight greater than 50 kg.\n\n          -  Diagnosis of ASD\n\n          -  Drug-refractory irritability, as defined as screening ABC Irritability subscale\n             (ABC-I) score of \u226518 AND 1) failure of clinically adequate treatment trials of both\n             aripiprazole and risperidone or 2) failure of at least three previous clinically\n             adequate drug trials targeting irritability (one trial must include aripiprazole or\n             risperidone), as confirmed by caregiver reports and medical record review when\n             available.\n\n          -  Stable dosing of all concomitant psychotropic medications (including those targeting\n             irritability) for four weeks prior to screening visit and during the study.\n\n          -  Presence of parent/guardian willing to serve as informant for behavioral outcome\n             measures and shipping control sample for Extracellular Signal-Related Kinase\n             biomarker (ERK) assay.\n\n        Exclusion Criteria:\n\n          -  Current use of more than two concomitant psychotropic drugs targeting irritability.\n\n          -  Current use of valproic acid.\n\n          -  Current use of drugs with known interaction with riluzole\n\n          -  Current use of drugs with concomitant glutamatergic or glutamatergic- modulating\n             action medications.\n\n          -  For female subjects of child bearing potential, a positive serum pregnancy test.\n\n          -  History of pancreatitis.\n\n          -  Hemoglobin less than or equal to 8.0 gm/dL.\n\n          -  Neutropenia with absolute neutrophil count less than or equal to 1.0 K/mcL.\n\n          -  Problems with kidney functioning, as assessed by lab work\n\n          -  Any major chronic medical or chronic respiratory illness considered to be\n             uncontrolled by the Principal Investigator."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "26 Years", 
            "minimum_age": "12 Years"
        }, 
        "enrollment": {
            "#text": "12", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 5, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02081027", 
            "org_study_id": "CIN001- Riluzole in Autism"
        }, 
        "intervention": [
            {
                "arm_group_label": "Riluzole", 
                "intervention_name": "Riluzole", 
                "intervention_type": "Drug", 
                "other_name": "Other name: Rilutek"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Riluzole"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "March 5, 2014", 
        "location": {
            "contact": {
                "email": "autism@cchmc.org", 
                "last_name": "Katie Friedmann, RN", 
                "phone": "513-636-0523"
            }, 
            "facility": {
                "address": {
                    "city": "Cincinnati", 
                    "country": "United States", 
                    "state": "Ohio", 
                    "zip": "45229"
                }, 
                "name": "Cincinnati Children's Hospital Medical Center"
            }, 
            "investigator": {
                "last_name": "Logan Wink, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Double-Blind, Placebo-Controlled, Cross-Over Pilot Study of Riluzole for Drug-Refractory Irritability in Autism Spectrum Disorders", 
        "overall_contact": {
            "email": "psychautism@cchmc.org", 
            "last_name": "Katie Friedmann, RN", 
            "phone": "513-636-0523"
        }, 
        "overall_official": {
            "affiliation": "Children's Hospital Medical Center, Cincinnati", 
            "last_name": "Logan Wink, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Clinical Global Impression-Improvement", 
                "safety_issue": "No", 
                "time_frame": "Change from baseline to end of week 14"
            }, 
            {
                "measure": "Aberrant Behavior Checklist- Irritability", 
                "safety_issue": "No", 
                "time_frame": "Change between baseline and end of each phase"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02081027"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Children's Hospital Medical Center, Cincinnati", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Children's Hospital Medical Center, Cincinnati", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}